| 50.17 -0.58 (-1.14%) | 04-19 14:08 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 62.52  |
1-year : | 64.6 |
| Resists | First : | 53.52 |
Second : | 55.31 |
| Pivot price | 52.24 |
|||
| Supports | First : | 50.65 |
Second : | 42.14 |
| MAs | MA(5) : | 51.44 |
MA(20) : | 52.18 |
| MA(100) : | 52.31  |
MA(250) : | 53.54 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 15.5 |
D(3) : | 22.5 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 62.88 | Low : | 43.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GMED ] has closed above bottom band by 8.1%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 52.14 - 52.44 | 52.44 - 52.76 |
| Low: | 50.27 - 50.6 | 50.6 - 50.95 |
| Close: | 50.58 - 51.15 | 51.15 - 51.77 |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Wed, 17 Apr 2024
Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues - Yahoo Movies UK
Tue, 16 Apr 2024
Globus Medical Schedules First Quarter Earnings Release and Conference Call - GlobeNewswire
Mon, 15 Apr 2024
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term - Yahoo Finance Australia
Sat, 13 Apr 2024
Globus Medical, Inc. (NYSE:GMED) Short Interest Up 32.4% in March - MarketBeat
Mon, 08 Apr 2024
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued - Simply Wall St
Mon, 08 Apr 2024
Globus Medical Breaks Above 200-Day Moving Average - Bullish for GMED - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 113 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 96.9 (%) |
| Shares Short | 7,760 (K) |
| Shares Short P.Month | 5,730 (K) |
| EPS | 1.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.31 |
| Profit Margin | 7.8 % |
| Operating Margin | 12.7 % |
| Return on Assets (ttm) | 4.7 % |
| Return on Equity (ttm) | 4.2 % |
| Qtrly Rev. Growth | 124.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 13.9 |
| EBITDA (p.s.) | 3.7 |
| Qtrly Earnings Growth | -78.9 % |
| Operating Cash Flow | 244 (M) |
| Levered Free Cash Flow | -347 (M) |
| PE Ratio | 47.42 |
| PEG Ratio | 1.2 |
| Price to Book value | 1.73 |
| Price to Sales | 3.65 |
| Price to Cash Flow | 23.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|